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ABSTRACT 
Objectives: The insights that people with cystic fibrosis have concerning their health are 
important given that aspects of health-related quality of life (HRQoL) are independent predictors 
of survival and a decrease in lung function is associated with a decrease in HRQoL over time. 
Cross-sectional data suggest that key variables, other than lung function, are also associated 
with HRQoL - although study results are equivocal. This work evaluates the relationship between 
these key demographic and clinical variables and HRQoL longitudinally.  
Design: Longitudinal observational study. Observations were obtained at seven time points: 
approximately every two years over a twelve year period.  
Setting: Large Adult Cystic Fibrosis Centre in the UK. 
Participants: 234 participants aged 14-48 years at recruitment.  
Outcome measure:  Nine domains of HRQoL (Cystic Fibrosis Quality of Life Questionnaire) in 
relation to demographic (age, gender) and clinical measures (FEV1% predicted, BMI, cystic 
fibrosis related diabetes, B. cepacia complex, totally implantable vascular access device, 
nutritional and transplant status).  
Results: A total of 770 patient assessments were obtained for 234 patients. The results of 
random coefficients modelling indicated that demographic and clinical variables were 
identified as being significant for HRQoL over time. In addition to lung function, transplant 
status, age, having a totally implantable vascular access device, cystic fibrosis related 
diabetes, BMI and B. cepacia complex impacted on many HRQoL domains longitudinally. 
Gender was important for the domain of Body image.  
Conclusion: Demographic and changes in clinical variables were independently associated 
with a change in health-related quality of life over time. Compared with these longitudinal data, 
cross-sectional data are inadequate when evaluating the relationships between HRQoL 
domains and key demographic and clinical variables, as they fail to recognise the full impact 
of the CF disease trajectory and its treatments on quality of life. 
 
Strengths and limitations of this study 
• This work provides the first longitudinal data that evaluate the association between 
changes in clinical variables and HRQoL in cystic fibrosis. 
• Participants were followed–up every two years over a twelve year period. 
• These longitudinal data highlight the inadequacy of cross-sectional data which fail to 
recognise the full impact of the CF disease trajectory and its treatments on HRQoL. 
• This was a single centre study  
• Clinical variables that were not evaluated included the frequency of pulmonary 
exacerbations and microbiological status.  
  
INTRODUCTION  
Over the last three decades advances in the care of people with cystic fibrosis (CF) have led 
to the median age of survival increasing steadily, so that in 2014, median survival had reached 
36.6 years in the UK.1 Greater longevity is at a cost of life-long adherence to a complex and 
burdensome daily regimen of up to four hours per day,2,3 which includes chest physiotherapy, 
daily enzyme replacement therapy, high-fat requirements, exercise and oral, inhaled and 
intravenous medication. With increasing age, patients may develop complications including 
CF related diabetes, allergic bronchopulmonary aspergillosis, atypical mycobacteria, 
osteoporosis and arthropathy. Despite the burdens that the disease and its treatments impose 
on them, people with CF are psychologically well-adjusted and generally report a good health-
related quality of life (HRQoL) on many domains of generic and CF specific measures.4-9 
Understanding the determinants for sustaining a good HRQoL with advancing CF disease 
may assist in the development of interventions to improve it.  
Cross-sectional studies have demonstrated that demographic and clinical variables appear to 
impact on life quality; with age,4-5 gender,5-7 lung transplant status and FEV17-9 most 
consistently associated with HRQoL.  However, while important associations were identified, 
much of the variation in HRQoL remained unexplained4,8,10,11 and causal relationships could 
not be ascertained. Although authors acknowledge that longitudinal work is required to 
understand these relationships, this is rarely undertaken and assumptions are simply 
extrapolated from cross-sectional data.  Over one or two years there is little change in HRQoL 
at the population level.12-14 Recently, two studies have linked HRQoL reporting over many 
years with clinical outcomes in CF. Patient-reported physical function has been shown to be 
an independent predictor of survival in CF15 and recent longitudinal work has demonstrated 
that, over a decade, both FEV1% predicted and HRQoL domains declined slowly, with a 
decrease in lung function being associated with a decrease in HRQoL domains.16  
In addition to lung function, cross-sectional data suggest that other key demographic and 
clinical variables are associated with HRQoL. This work aims to evaluate the relationship 
between these variables and HRQoL longitudinally.  
 
METHODS  
Subjects and procedure 
All patients who attended a large Adult Cystic Fibrosis Centre in the UK were approached to 
take part in the study. The Centre followed standard treatment protocols and annual reviews 
were undertaken as close to the patient’s birthday as possible, predominantly when they were 
clinically stable. The CFQoL17 was mailed out every two years for completion prior to their 
clinic visit at which demographic and clinical variables were recorded. People with CF were 
followed–up, at approximately two yearly intervals, for twelve years. There were seven 
assessments (time points T1-T7 from 1998 to 2010). At each time point patients provided 
consent for their participation in accordance with ethical committee approval. 
Measures 
At each time point demographic, clinical and HRQoL variables were collected. Age, gender, 
FEV1% predicted, BMI, and whether the person had cystic fibrosis related diabetes (CFRD), 
B. cepacia complex or a totally implantable vascular access device (TIVAD) were recorded. 
Nutritional status (no oral calorie supplements, prescribed oral calorie supplements or 
prescribed enteral tube feeds) and lung transplantation (listed or received transplant) were 
also documented.  
Quality of Life was measured using the Cystic Fibrosis Quality of Life Questionnaire 
(CFQoL).17 The CFQoL was developed and validated in the UK and was therefore the most 
appropriate CF-specific HRQoL measure for this UK sample. The instrument measures nine 
domains of functioning: Physical functioning, Social functioning, Emotional responses, 
Treatment issues, Chest symptoms, Body image, Interpersonal relationships, Career 
concerns and Concerns for the future. The psychometric properties of the instrument are good. 
Internal reliability of the domains was demonstrated using Cronbach’s alpha coefficients 
(range 0.72-0.92, median 0.89) and item to total domain score correlations. Concurrent validity 
with three appropriate SF-36 domains (range r = 0.64-0.74), known groups validity between 
different levels of disease severity, sensitivity across transient changes in health (effect size 
range, d = 0.56-1.95) and test-retest reliability (r = 0.74-0.96, median 0.91) were found to be 
robust. Each domain has a minimum score of 0% and a maximum score of 100%, with higher 
scores reflecting a better quality of life. 
Statistical analyses 
The modelling was carried out using all patients who entered the study. Not all patients entered 
the study at time point one (T1), but joined the study at later time points (T2 to T7). Some 
patients died or dropped out during the twelve years, but their available data were still included 
in the analyses. Hence, the analyses were not based only on survivors.     
Patient characteristics at all the times combined were described by summary statistics. The 
longitudinal relationships between the nine domains of CFQoL and the eleven variables 
recording patient characteristics were modelled using regression models with fixed and 
random coefficients. Random coefficients allowed the observations on an individual patient to 
be predicted by an individual random coefficient which was assumed to be sampled from a 
population of normally distributed coefficients across individuals. This type of modelling has 
been used frequently for longitudinal studies.18,19 For each CFQoL domain; CFQoL=100xS/N 
where S was the domain score and N was the maximum domain score. Maximum scores for 
the domains were: Physical functioning [50], Social functioning [20], Emotional responses [40], 
Treatment issues [15], Chest symptoms [20], Body image [15], Interpersonal relationships 
[50], Career concerns [20] and Concerns for the future [30]. Statistical analysis of HRQoL is 
challenging because of the ‘ceiling effects’ for all HRQoL scales which have a maximum of 
100% 20 and because domain scores (S) are discrete measures that  only have values which 
correspond to whole numbers; for example with Social functioning N is 20 and so Social 
functioning can take only the values 100%, 95%, 90% etc. 
Therefore, binomial regression with fixed and random coefficients was chosen as a suitable 
modelling framework because the binomial is a discrete distribution for a score (S) that has a 
prescribed maximum (N). Binomial regression predicts within the range 0% to 100% because 
the model predicts the logit transformation of HRQoL (CFQoL on the logit scale), analogous 
to logistic regression. Models were fitted using the software MLwiN.21  
The models estimated the means, variances and covariances of the random coefficients for 
the quantitative covariates FEV1% predicted, BMI and the model intercept. The categorical 
predictors of gender, CFRD, nutritional status (oral supplements and tube feeding), TIVAD, B. 
cepacia complex, and transplant status (listed for or received transplant) were included as 
fixed effects. Age, although quantitative, was included as a fixed effect because age changes 
deterministically with time. The random coefficients were tested statistically to determine 
whether each should be retained as a random coefficient or could be included as fixed. For 
each CFQoL domain the maximal model was fitted which included all eleven patient variables 
and a variable was judged as having a significant association with a CFQoL domain if the P-
value for the variable in the maximal model was less than 0.1(10% significance). This 
significance level was chosen because it is conventionally used for retaining terms in a multiple 
regression analysis with many variables. For the random coefficients the P-value for the 
coefficient mean was used and for the fixed effects the P-value of the fixed coefficient was 
used to determine significance. For each variable in the maximal model, the coefficients were 
used to calculate the typical change in HRQoL (%) from an initial value of HRQoL. The initial 
HRQoL(%) was transformed to the logit scale, the coefficient was applied and then the result 
was transformed back to the HRQoL scale. Initial HRQoL in the range 20% to 80% was used 
and the greatest and smallest changes in HRQoL were recorded.  
 
 
RESULTS 
The intention was to follow individuals every two years but, on occasion, some patients failed 
to attend annual review or participate in the study, or had died. Therefore, Table 1 presents 
the number of patients who participated for each total number of study time points (T1-T7) and 
the consequent number of patient assessments which the clinic visits contributed to the 
longitudinal data. A total of 770 completed patient assessments were obtained for 234 
patients. The median number of completed patient assessments was 3 with interquartile range 
2 to 5 assessments. 
 
 
Table 1 Numbers of patients and patient assessments.      
Number of  
time-points per patient 
Number of  
patients 
Number of  
patient assessments 
1 54 54 
2 51 102 
3 31 93 
4 32 128 
5 25 125 
6 19 114 
7 22 154 
Total 234 770 
 
 
 
The demographic, clinical characteristics and HRQoL measures recorded at all the 
assessments combined are shown in Table 2. For the categorical variables, the percentage 
of assessments at which the patients had CFRD, oral supplements etc. are provided. For the 
quantitative variables such as age, the mean, standard deviation and range are shown.     
 
 
 
 
 
 
 
 
 
Table 2 Characteristics of the patient assessments. 
 
 N (%) Range Mean (SD) 
Total patient assessments 770 (100.0%)   
Female patient 445 (57.8%)   
Oral supplements taken 254 (33.0%)   
Enteral tube feeds taken 122 (15.8%)   
CFRD present  287 (37.3%)   
TIVAD fitted 402 (52.2%)   
B. cepacia complex present 58 (7.5%)   
Listed for transplant 35 (4.5%)   
Received transplant 97 (12.6%)   
Ages (years)  14 - 57 28.5 (  8.2) 
FEV1% predicted   12 -133 58.3 (23.8) 
BMI    15 - 34 21.8 (  3.1) 
Physical functioning  2 - 100 83.0 (20.5) 
Social functioning  0 - 100 84.7 (21.5) 
Emotional responses  8 - 100 78.6 (20.6) 
Treatment issues  0 - 100 74.7 (22.5) 
Chest symptoms  0 - 100 76.6 (23.2) 
Body image  0 - 100 69.8 (24.7) 
Interpersonal relationships  2 - 100 64.5 (22.4) 
Career concerns  0 - 100 61.7 (29.4) 
Concerns for the future  0 - 100 45.0 (25.1) 
           
 
Longitudinal relationships between HRQoL and demographic and clinical variables  
Each model for a domain of HRQoL included all demographic and clinical variables and the 
model coefficients are shown by variable in Figures 1 and 2. Demographic and clinical 
variables which were significant at the 10% level were extracted and are presented in Table 3 
by HRQoL domain. The coefficients for age and FEV1% predicted were scaled (5 years 
increase and 10% decrease respectively) to provide clinically meaning change since HRQoL 
changes slowly for these variables. In cross-sectional work, predominantly FEV1% predicted 
and transplant status were significantly associated with HRQoL7-9. Longitudinally, in addition 
to lung function and transplant status, age, having a TIVAD, CFRD, BMI and B. cepacia 
complex were important for more than half of the HRQoL domains. 
 
 Table 3 Variables significant at the 10% level in the multiple regression models together with 
adjusted coefficients, standard errors and significance levels. 
Domain Coefficient (SE) P-value Domain Coefficient (SE) P-value 
Physical functioning  
Age (5y increase) 
BMI (1 unit decrease) 
TIVAD 
B. cepacia complex 
FEV1% (10% decrease) 
Listed for transplant  
 
-0.10 (0.03) 
-0.10 (0.04) 
-0.34 (0.08) 
-0.36 (0.18) 
-0.20 (0.04) 
-0.37 (0.11) 
 
 
<0.001 
0.007 
<0.001 
0.053 
<0.001 
<0.001 
 Social functioning 
Age (5y increase) 
CFRD 
BMI (1 unit decrease) 
B. cepacia complex 
FEV1% (10% decrease) 
Listed for transplant  
Received transplant 
 
 
-0.11 (0.04) 
-0.28 (0.11) 
-0.07 (0.04) 
-0.65 (0.25)  
-0.13 (0.05) 
-0.45 (0.15) 
-0.73 (0.27) 
 
0.008 
0.015 
0.078 
0.008 
0.004 
0.004 
0.007 
Emotional responses 
Age (5y increase) 
CFRD 
TIVAD 
FEV1% (10% decrease) 
Listed for transplant  
 
-0.19 (0.03) 
-0.16 (0.08) 
-0.13 (0.07) 
-0.11 (0.03) 
-0.35 (0.11) 
 
<0.001 
0.032 
0.087 
<0.001 
0.002 
 Treatment issues 
Age (5y increase) 
BMI (1 unit decrease) 
Oral supplements 
TIVAD 
B. cepacia complex 
FEV1% (10% decrease) 
Listed for transplant  
Received transplant 
 
 
-0.18 (0.03) 
-0.09 (0.02) 
-0.19 (0.10) 
-0.36 (0.09) 
-0.39 (0.20) 
-0.06 (0.03) 
-0.35 (0.15) 
0.67 (0.21) 
 
<0.001 
<0.001 
0.068 
<0.001 
0.045 
0.078 
0.019 
0.001 
Chest symptoms 
Age (5y increase) 
CFRD 
BMI (1 unit decrease) 
TIVAD 
B. cepacia complex 
FEV1% (10% decrease) 
Listed for transplant  
Received transplant 
 
 
-0.07 (0.03) 
-0.21 (0.10) 
-0.10 (0.03) 
-0.35 (0.09) 
-0.48 (0.19) 
0.17 (0.03) 
-0.41 (0.13) 
0.79 (0.21) 
 
0.054 
0.027 
0.001 
<0.001 
0.013 
<0.001 
0.002 
<0.001 
 Body image 
Female 
CFRD 
BMI (1 unit decrease) 
Enteral tube feeds 
TIVAD 
B. cepacia complex 
Received transplant 
 
0.58 (0.13) 
-0.22 (0.09) 
-0.15 (0.02) 
-0.24 (0.13) 
-0.30 (0.09) 
-0.57 (0.18) 
-0.39 (0.17) 
 
<0.001 
0.013 
<0.001 
0.069 
0.001 
0.002 
0.022 
Interpersonal relationships    Career concerns   
Age (5y increase) 
CFRD 
Oral supplements 
TIVAD 
FEV1% (10% decrease) 
 
-0.08 (0.02) 
-0.11 (0.06) 
0.11 (0.06) 
-0.16 (0.06) 
-0.10 (0.03) 
<0.001 
0.081 
0.081 
0.011 
0.001 
 Age (5y increase) 
TIVAD 
FEV1% (10% decrease) 
Listed for transplant  
Received transplant 
-0.15 (0.03) 
-0.46 (0.08) 
-0.16 (0.03) 
-0.31 (0.14) 
-0.71 (0.19) 
<0.001 
<0.001 
<0.001 
0.019 
<0.001 
Concerns for the future      
Age (5y increase) 
Female 
BMI (1 unit decrease) 
TIVAD 
Listed for transplant  
Received transplant 
-0.19 (0.03) 
-0.26 (0.13) 
-0.06 (0.02) 
-0.22 (0.07) 
-0.37 (0.12) 
0.41 (0.17) 
<0.001 
0.057 
0.010 
0.001 
0.002 
0.015 
    
 
 
The coefficients presented in Table 3 and Figures 1 and 2 apply to the logit scale (as described 
in the method section). This has the consequence that the actual change in HRQoL depends 
on the initial reported value of HRQoL before the change. To aid interpretation, Table 4 shows 
the typical change in HRQoL domains for initial values in the range of 20%-80%. For age (5 
year increase), BMI (1 unit decrease), FEV1% predicted (10% decrease), oral supplements 
and enteral tube feeds, small changes, generally less than 5% were predicted. Having CFRD, 
TIVAD, B. cepacia complex and being listed for lung transplant predicted greater decrements 
across HRQoL domains. The largest changes in HRQoL were associated with having received 
a lung transplant; large increases in HRQoL occurred for Treatment issues, Chest symptoms, 
Concerns for the future and Emotional responses. Conversely, receiving a transplant 
predicted large decreases in Social functioning, Career concerns and Body image.       
 
Table 4 Predicted typical change in domain specific HRQoL (%) from an initial HRQoL in the 
range 20% to 80%. The change is a decrease unless otherwise indicated by *. 
Domain Age 
5y increase 
BMI 
1 unit decrease 
FEV1% 
10% decrease 
CFRD TIVAD 
Physical functioning  1.5 – 2.5 1.5 – 2.4 3.0 – 4.9 1.1 – 1.7 4.9 –   8.4 
Social functioning 1.7 – 2.8 1.2 – 1.8 2.0 – 3.3 2.2 – 6.9 1.7 –   2.8 
Emotional responses 2.8 – 4.6 0.7 – 1.1 1.7 – 2.7 2.5 – 4.1 2.0 –   3.2 
Treatment issues 2.8 – 4.6 1.4 – 2.2 0.9 – 1.9 1.8 – 2.9 5.2 –   9.0 
Chest  symptoms 1.0 – 1.6 1.5 – 2.4 2.6 – 4.2 3.2 – 5.3 5.0 –   8.5 
Body image 0.1 – 0.2 2.3 – 3.8 0.1 – 0.2 3.3 – 5.6 4.3 –   7.3 
Interpersonal relationships 1.3 – 2.0 0.1 – 0.1 1.6 – 2.6 1.7 – 2.8 2.4 –   3.9 
Career concerns 2.2 – 3.6 0.6 – 0.9 2.4 – 3.9 0.8 – 1.2 6.4 – 11.5 
Concerns for the future 2.8 – 4.6 0.9 – 1.4 0.6 – 0.9 1.2 – 1.8* 3.3 –   5.5 
 Oral 
supplements 
Enteral  
tube feeds 
B. cepacia 
complex 
Listed for 
transplant 
Received 
transplant 
Physical functioning  0.9 – 1.4 1.8 – 2.7* 5.1 –   8.8 5.3 –   9.2   4.2 –   7.1 
Social functioning 1.5 – 2.3 2.2 – 3.5 8.5 – 16.1§ 6.2 – 11.1   9.2 – 18.0 
Emotional responses 1.4 – 2.2 0.6 – 1.0 3.6 –   6.0 5.0 –   8.6   5.2 –   7.4* 
Treatment issues 2.8 – 4.7 2.3 – 3.7 5.6 –   9.7 5.0 –   8.7 12.9 – 16.6* 
Chest  symptoms 1.7 – 2.7 1.3 – 2.0* 6.6 – 11.8 5.7 – 10.0 15.4 – 19.4* 
Body image 1.1 – 1.7 3.6 – 6.0 7.6 – 14.0 0.7 –   1.1   5.5 –   9.7 
Interpersonal relationships 1.8 – 2.8* 2.4 – 3.5* 0.2 –   0.3 1.7 –   2.7   0.2 –   0.3 
Career concerns 0.6 – 0.9 1.8 – 3.0 0.7 –   1.0* 4.6 –   7.9   9.0 – 17.5 
Concerns for the future 0.0 – 0.1* 2.0 – 3.2 1.9 –   3.2 5.3 –   9.2   7.3 – 10.1* 
§Interpretation of table values: With colonisation with B. cepacia complex, Social functioning% is expected to decline by 
between 8.5 and 16.1 points depending on the Social functioning% domain score before colonisation. 
 
 
 
DISCUSSION 
This is a longitudinal observational study and, as such, it has the advantage over a cross-
sectional study of being able to determine temporality. For this reason, it is justifiable to 
interpret demographic and clinical changes as having impact on HRQoL. Hence, this work has 
demonstrated that the demands created by the CF disease trajectory and its treatments 
profoundly impact all aspects of a person’s quality of life. Demographic and clinical measures 
in CF are highly inter-related and the need to separate out the individual effects of these 
measures on patient HRQoL presents a considerable challenge. The modelling approach 
taken here has responded well to this challenge and has provided fundamental insight into the 
way in which changes in these measures impact on HRQoL.  
In contrast to previous cross-sectional work, a greater number of demographic and clinical 
variables were identified as impacting HRQoL over time. This longitudinal work confirms the 
cross-sectional findings that advancing age, lung function and transplantation are important 
predictors of outcome across many domains of life quality. Variables which did not consistently 
emerge as important in cross-sectional regression models have also now been shown to be 
independent predictors of HRQoL longitudinally. These include BMI, having a totally 
implantable vascular access device, cystic fibrosis related diabetes and B. cepacia complex. 
We have recently reported data that assessed the natural progression of HRQoL reporting in 
cystic fibrosis over many years.16 Patient-reported HRQOL declines slowly over time at 
approximately 1% per year. Over a decade, population score decline was different for each 
CFQoL domain (Physical function -8.0, Social function -9.2, Emotional response -8.3, 
Treatment issues -13.7, Chest symptoms -9.4, Body image -6.0, Interpersonal relationships -
6.8, Career concerns-15.9, Future concerns -13.2). Knowing the natural rate of change in 
HRQoL domains provides a benchmark against which changes due to CF complications or 
interventions can be compared and should help to inform the clinical relevance of HRQoL 
changes. 
Previous work demonstrated that both FEV1% predicted and HRQoL declined slowly, 
however, a decrease in lung function was associated with a decrease in HRQoL over time.16  
FEV1% predicted was significantly associated with all domains of HRQoL except Body image 
and these analyses have substantially supported that finding. Previously, it was reported that 
FEV1% declines on average by 8.8% and that Physical functioning declines on average by 
8.0% for survivors over one decade. This accords with the results shown here which indicate 
that a decade increase in age alone was associated with a 3.0 to 5.0% decline in Physical 
functioning. Additionally an 8.8% decline in FEV1% was associated with a 2.6 to 4.3% decline 
in physical functioning producing a total decline of between 5.6 to 9.3% in physical functioning; 
any small differences being due to the increased risk of change in clinical condition such as 
the onset of CFRD.  
An improvement in HRQoL is a compelling argument for lung transplantation.22,23 Those in 
need of transplantation report restrictions on most aspect of their HRQoL.24,25 Generally, CF 
lung transplant recipients have been reported to have good outcomes with high levels of life 
quality in some HRQoL domains.26-28 However, longitudinal data comparing pre and post 
transplantation is lacking. The current modelling estimated the effect of undergoing a lung 
transplant on HRQoL by evaluating the change between the mean pre and post 
transplantation values. As expected, being listed for transplant predicted a profoundly negative 
impact on HRQoL. However, following transplantation only the domains of Treatment issues, 
Chest symptoms, Emotional functioning and Concerns for the future were radically improved. 
Transplant was associated with continuing poor HRQoL for Physical functioning, and a 
considerable further deterioration in Social functioning, Career concerns and perceived Body 
image. This highlights the importance of monitoring HRQoL over time. 
Cross-sectional work highlighted a complex relationship between BMI, Body image and 
gender.4 These longitudinal data have clarified this matter. Females typically report a better 
body image than males4-7,29 and this association was confirmed from these longitudinal data.  
The model coefficient for gender for Body image was 0.58 (p<0.001) showing that females 
had a significantly higher Body image than males over time. However, the model coefficient 
for Body image for a one unit decrease in BMI was -0.154 for males and females combined (-
0.159 for males and -0.162 for females separately), so although females have a higher level 
of Body image, a decrease of one unit BMI results in the same decrease in perceived Body 
image for both males and females. Previous work had indicated that both males and females 
receiving nutritional interventions generally desired to be heavier, although females still only 
desired a BMI of 19.29 When BMI falls below what is desired, Body image HRQoL decreases 
for both genders. There was little negative impact on HRQoL as a result of nutritional 
interventions over time (oral nutritional supplements and enteral tube feeding), suggesting that 
the interventions to maintain BMI were successful. The single exception to this was the 
association between enteral tube feeds and Body image.  
Totally implantable vascular access devices (TIVADs) have emerged as an effective means 
for intermittent venous access for therapeutic infusions30 nevertheless; having an access 
device predicted a poorer HRQoL for virtually all HRQoL domains over time. The reasons for 
this are unclear and we did not collect data on complication rates or the nature of 
complications. TIVADs provide the opportunity and social benefits of home intravenous 
therapy but Body image issues and the interference with daily activities (e.g. car seatbelts, 
engaging in sport)31 remain a continuing concern.  
CFRD is considered to be a condition in its own right. It is associated with a decrease in Social 
functioning, Chest symptoms, Body image and Emotional responses; although it is surprising 
that it does not predict a greater decline across HRQoL domains longitudinally. While it does 
not lessen the impact CFRD has on HRQoL, it is noteworthy that diabetes in people with CF 
has been shown to have a less negative impact on HRQoL than in those with Type 1 diabetes 
mellitus (T1DM). Both groups experienced hypoglycaemia, but loss of consciousness or 
needing help was more common in T1DM patients and symptoms suggestive of 
hypoglycaemia were less of a problem for CFRD patients in terms of severity, with T1DM 
patients having more neuroglycopenic symptoms.32  
B. cepacia complex had an immense negative impact on Social functioning and Body image, 
together with a considerable decline in Chest symptoms, Treatment issues and Physical 
functioning. This may be anticipated as during the collection of these data patients with B. 
cepacia complex were segregated at clinic, on wards and at scientific meetings.33 People with 
CF are aware of the associated increase in morbidity and mortality and the knowledge of 
colonisation with the bacteria brings further uncertainty about the future. Hence, one minor 
limitation of this study is that it commenced prior to the routine clinical classification of 
genomovar status, although this alone cannot predict clinical outcome in any individual 
patient.34 
Further limitations are that this was a single Centre study and several important variables were 
not evaluated, including the frequency of pulmonary exacerbations35 and microbiological 
status (Pseudomonas aeruginosa, B. cepacia complex, genomovar classification, Allergic 
Broncho Pulmonary Aspergillosis). The longitudinal data analysis showed that many more 
demographical and clinical variables were associated with HRQoL than in cross-sectional 
work. This was achieved by estimating coefficients that measured the different average level 
of HRQoL between all data recorded before and all data recorded after a change in a clinical 
variable. A limitation of this analysis was that it did not estimate HRQoL in relation to the time 
since the change occurred. So, for example, transplantation may have resulted in a relatively 
large decrease in a HRQoL domain for the first few years followed by recovery in the HRQoL 
subsequently. A more sophisticated analysis would be required to determine any such pattern.  
 
The long-term determinants of life quality are becoming clearer and repeated HRQoL 
assessments should be able to provide useful information concerning the individual’s 
adaptation to the disease and be used to improve the care delivered to patients.  HRQoL 
measurement in CF remains largely a research endeavour, although monitoring HRQoL in 
routine clinical care has been shown to be feasible.12 Web-based completion of HRQoL scales 
may allow screening and the detection of problems, the monitoring of patient’s difficulties over 
time, and improving clinician – patient communication by addressing these issues during a 
clinical consultation. Additionally, the input of these data into registries should enable robust 
evaluations of HRQoL over time and allow further evaluation of patient-reported outcomes in 
predicting morbidity and survival. The challenge for the future is to use the available 
information when designing and interpreting the results of studies, and to develop and 
evaluate psychological interventions that could improve HRQoL, or mitigate the effects of 
interventions known to impact adversely on HRQoL, for people with CF. 
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Figure 1. Coefficients from the multilevel models for six demographic and clinical variables. 
The limits show plus and minus one standard error. Coefficients are not significant (blue 
bars), significant at the 10% level (yellow bars) and significant at the 5% level (red bars). 
 
Figure 2. Coefficients from the multilevel models for five demographic and clinical variables. 
The limits show plus and minus one standard error. Coefficients are not significant (blue 
bars), significant at the 10% level (yellow bars) and significant at the 5% level (red bars). 
 
